Palo Alto Investors’s Sophiris Bio, Inc. SPHS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
Sell
-247,000
Closed -$91K 40
2019
Q4
$91K Hold
247,000
0.01% 36
2019
Q3
$144K Hold
247,000
0.01% 36
2019
Q2
$209K Hold
247,000
0.01% 35
2019
Q1
$245K Hold
247,000
0.01% 34
2018
Q4
$205K Hold
247,000
0.01% 34
2018
Q3
$689K Hold
247,000
0.03% 33
2018
Q2
$694K Hold
247,000
0.03% 34
2018
Q1
$496K Hold
247,000
0.02% 35
2017
Q4
$561K Hold
247,000
0.02% 36
2017
Q3
$530K Hold
247,000
0.02% 38
2017
Q2
$543K Hold
247,000
0.03% 34
2017
Q1
$699K Hold
247,000
0.03% 35
2016
Q4
$692K Hold
247,000
0.04% 34
2016
Q3
$768K Sell
247,000
-247,000
-50% -$929K 0.04% 37
2016
Q2
$1.06M Hold
494,000
0.08% 39
2016
Q1
$711K Hold
494,000
0.06% 41
2015
Q4
$879K Buy
494,000
+302,400
+158% +$448K 0.05% 40
2015
Q3
$163K Hold
191,600
0.01% 47
2015
Q2
$150K Hold
191,600
0.01% 45
2015
Q1
$111K Hold
191,600
0.01% 46
2014
Q4
$103K Sell
191,600
-101,300
-35% -$235K 0.01% 46
2014
Q3
$858K Hold
292,900
0.06% 41
2014
Q2
$656K Hold
292,900
0.05% 40
2014
Q1
$975K Hold
292,900
0.08% 35
2013
Q4
$1.08M Buy
292,900
+237,900
+433% +$1.01M 0.1% 32
2013
Q3
$257K Buy
+55,000
New +$254K 0.03% 33

Other funds holding SPHS

Palo Alto Investors's SPHS Position: Q1 2020 in Review

Palo Alto Investors sold out of Sophiris Bio, Inc. (SPHS) in Q1 2020, closing a stake of 247,000 shares — an estimated $91K sold.

Palo Alto Investors first reported a position in SPHS in Q3 2013 and held it in 26 quarters. The position peaked at $1.08M in Q4 2013. 3 funds tracked by Wall St. Rank hold SPHS as of Q1 2020.

  • Palo Alto Investors reported no remaining Sophiris Bio, Inc. position as of Q1 2020 after selling out during the quarter.
  • Palo Alto Investors sold 247,000 Sophiris Bio, Inc. shares in Q1 2020, an estimated $91K.
  • Palo Alto Investors first reported a position in Sophiris Bio, Inc. in Q3 2013 and held it in 26 quarters.
  • Palo Alto Investors's Sophiris Bio, Inc. position peaked at $1.08M in Q4 2013.
  • 3 funds tracked by Wall St. Rank held Sophiris Bio, Inc. as of Q1 2020.

Based on Palo Alto Investors's 13F filing for Q1 2020, filed 15 May 2020.